Colorectal Cancer
Universal DX Closes Series B Round to Begin Clinical Trial for CRC Screening Test
The firm's blood test uses next-generation sequencing and bioinformatics to identify methylated DNA patterns and fragments from colorectal cancer tumors in the blood.
Guardant Health Q2 Revenues Grow 29 Percent; Firm Raises Full-Year Guidance
Guardant reached a major milestone in Q2 with the FDA approval of its Guardant Shield liquid biopsy colon cancer screening test.
Colorectal Cancer Subgroups, Prognostic Insights Emerge From New Omics Studies
Two research teams identified driver genes, mutations, and pathways involved in colorectal cancer along with new subgroups, mutational signatures, and prognostic insights.
Exact Sciences Reports 12 Percent Q2 Revenue Jump, Breaks Quarterly Test Volume Record
The company said it screened more that 1 million people for colorectal cancer during the quarter, and also tested a record number with its Oncotype DX breast cancer test.
US Patent Trial and Appeal Board to Review Exact Sciences Patent Contested by Geneoscopy
The appeal board determined that Geneoscopy has a "reasonable likelihood" of proving at least one claim the company had alleged in requesting the review.